PubMed

Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Branco CC, Pereirinha T, Cabral R, Pacheco PR, Mota-Vieira L.

Thromb J. 2009 Jun 18;7:9.PMID: 19538716 [PubMed - in process]Related articlesFree article

Genetic signature of the São Miguel Island population (Azores) assessed by 21 microsatellite loci.

Branco CC, Pacheco PR, Cabral R, Vicente AM, Mota-Vieira L.

Am J Hum Biol. 2008 Jan-Feb;20(1):118-20.PMID: 17990326 [PubMed - indexed for MEDLINE]Related articles

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Scott SA, Edelmann L, Kornreich R, Desnick RJ.

Am J Hum Genet. 2008 Feb;82(2):495-500. Epub 2008 Jan 17.PMID: 18252229 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.

Palacio L, Falla D, Tobon I, Mejia F, Lewis JE, Martinez AF, Arcos-Burgos M, Camargo M.

Clin Appl Thromb Hemost. 2010 Feb;16(1):83-90. Epub 2009 Jun 29.PMID: 19567378 [PubMed - in process]Related articles

Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis.

Ibrahim S, El Dessokiy O.

Clin Exp Nephrol. 2009 Oct;13(5):501-7. Epub 2009 May 26.PMID: 19466593 [PubMed - indexed for MEDLINE]Related articles

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12.PMID: 19077919 [PubMed - indexed for MEDLINE]Related articles

Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.

Kuanprasert S, Dettrairat S, Palacajornsuk P, Kunachiwa W, Phrommintikul A.

J Med Assoc Thai. 2009 Dec;92(12):1597-601.PMID: 20043560 [PubMed - in process]Related articles

UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

Pacheco PR, Brilhante MJ, Ballart C, Sigalat F, Polena H, Cabral R, Branco CC, Mota-Vieira L.

Mol Diagn Ther. 2009;13(4):261-8. doi: 10.2165/11317170-000000000-00000.PMID: 19712005 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.PMID: 18698879 [PubMed - indexed for MEDLINE]Related articles

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. Epub 2009 Mar 17.PMID: 19297219 [PubMed - indexed for MEDLINE]Related articles

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, Hatemi AC, Siva A, Saip S, Johnson JA.

Eur J Clin Pharmacol. 2008 Sep;64(9):889-94. Epub 2008 Jun 10.PMID: 18542936 [PubMed - indexed for MEDLINE]Related articles

Distribution of CYP2C9 and VKORC1 Risk Alleles for Warfarin Sensitivity and Resistance in the Israeli Population.

Efrati E, Elkin H, Sprecher E, Krivoy N.

Curr Drug Saf. 2010 Mar 7. [Epub ahead of print]PMID: 20210733 [PubMed - as supplied by publisher]Related articles

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use.

Genet Med. 2008 Feb;10(2):139-50.PMID: 18281922 [PubMed - indexed for MEDLINE]Related articles

Role of Thrombotic Risk Factors in End-Stage Renal Disease.

Tripathi G, Sankhwar SN, Sharma RK, Baburaj VP, Agrawal S.

Clin Appl Thromb Hemost. 2009 Jun 10. [Epub ahead of print]PMID: 19520684 [PubMed - as supplied by publisher]Related articles

Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history.

Oliveira E, Pereira R, Amorim A, McLeod H, Prata MJ.

Pharmacogenomics. 2009 Sep;10(9):1413-22.PMID: 19761365 [PubMed - indexed for MEDLINE]Related articles

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

Haug KB, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, Kierulf P, Seljeflot I, Arnesen H, Brørs O.

Thromb J. 2008 Jun 17;6:7.PMID: 18559094 [PubMed - in process]Related articlesFree article

The largest prospective warfarin-treated cohort supports genetic forecasting.

Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P.

Blood. 2009 Jan 22;113(4):784-92. Epub 2008 Jun 23.PMID: 18574025 [PubMed - indexed for MEDLINE]Related articlesFree article

Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients.

Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, Habano W, Fukushima N, Nakai K, Obara W, Fujioka T, Suwabe A, Gurwitz D.

Pharmacogenomics. 2007 Jul;8(7):713-9.PMID: 18240904 [PubMed - indexed for MEDLINE]Related articles

[Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements]

Yang J, Miao LY, Huang CR, Shen ZY, Jiang WP.

Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Feb;36(2):137-40. Chinese. PMID: 19099951 [PubMed - indexed for MEDLINE]Related articles

Warfarin pharmacogenomics.

Cavallari LH, Limdi NA.

Curr Opin Mol Ther. 2009 Jun;11(3):243-51. Review.PMID: 19479657 [PubMed - indexed for MEDLINE]Related articles